Join us for a virtual KOL event with HTG Molecular Diagnostics, Inc. (HTG), featuring Robert Spitale, PhD (University of California, Irvine), discussing the use of RNA profiling in the drug discovery process to better uncover mechanism of action and refine the drug screening processes.

HTG will present results from the application of its transcriptome-informed drug discovery process. Specifically, differential regulation of the ferroptosis pathway by structurally similar compounds that target mTOR will be offered as an example of how RNA profiling can aid in understanding  post-target engagement consequences and expand our understanding of the biological implications of compound treatment.

HTG is actively using its transcriptome-informed approach to drug discovery to design and further refine small-molecule chemical libraries. The goal of this approach is to enable the selection and characterization of de-risked candidate molecules across selected therapeutic targets of interest leading to potential business development and licensing opportunities in various therapeutic areas.

A live question and answer session will follow the presentations.